CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

UmifenovirWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (5)

Name (Synonyms) Correlation
drug1308 Standards of Care Wiki 1.00
drug690 Interferon-β 1a Wiki 1.00
drug1251 Single Dose of Hydroxychloroquine Wiki 0.71
drug749 Lopinavir / Ritonavir Wiki 0.58
drug370 Convalescent plasma Wiki 0.32

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D003289 Convalescence NIH 0.50
D045169 Severe Acute Respiratory Syndrome NIH 0.06
D018352 Coronavirus Infections NIH 0.05

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Efficacy and Safety of Umifenovir as an Adjuvant Therapy Compared to the Control Therapeutic Regiment of Interferon Beta 1a, Lopinavir / Ritonavir and a Single Dose of Hydroxychloroquine in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial

The present study is a randomized, double-blind, placebo-controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical Education Center in Tehran. Patients will be randomly assigned to the two arms of the study and after completing the course of treatment and collecting and analyzing the necessary information from each patient, the results of the study will be published both on this site and in the form of an article in a reputable international journal.

NCT04350684 COVID-19 Drug: Umifenovir Drug: Interferon-β 1a Drug: Lopinavir / Ritonavir Drug: Single Dose of Hydroxychloroquine Drug: Standards of Care

Primary Outcomes

Description: Improvement of two points on a seven-category ordinal scale (recommended by the World Health Organization: Coronavirus disease (COVID-2019) R&D. Geneva: World Health Organization) or discharge from the hospital, whichever came first.

Measure: Time to clinical improvement

Time: From date of randomization until 14 days later.

Secondary Outcomes

Description: If the patient dies, we have reached an outcome.

Measure: Mortality

Time: From date of randomization until 14 days later.

Description: Pulse-oxymetry

Measure: SpO2 Improvement

Time: Days 1, 2, 3, 4, 5, 6, 7 and 14.

Description: Incidence of new mechanical ventilation use

Measure: Incidence of new mechanical ventilation use

Time: From date of randomization until 14 days later.

Description: Duration of hospitalization (days)

Measure: Duration of hospitalization

Time: From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to 14 days.

Description: With incidence of any serious adverse effects, the outcome has happened.

Measure: Cumulative incidence of serious adverse events

Time: Days 1, 2, 3, 4, 5, 6, 7 and 14.

No related HPO nodes (Using clinical trials)